Athenex, Inc. (NASDAQ:ATNX) Short Interest Update
Athenex, Inc. (NASDAQ:ATNX) Short Interest Update
Athenex, Inc. (NASDAQ:ATNX – Get Rating) was the target of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 3,030,000 shares, a decrease of 12.7% from the October 31st total of 3,470,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 2.7 days.
Athenex, Inc.（纳斯达克股票代码：ATNX — Get Rating）是11月空头利率大幅下降的目标。截至11月15日，空头利率共计3,03万股，较10月31日的347万股下降了12.7％。根据1,140,000股的平均每日成交量，目前空头利率为2.7天。
Athenex Price Performance
Athenex 价格表现
Shares of ATNX stock opened at $0.20 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.49 and a debt-to-equity ratio of 3.08. The business's fifty day simple moving average is $0.21 and its 200-day simple moving average is $0.41. Athenex has a 12-month low of $0.16 and a 12-month high of $1.74.
周一，ATNX股票开盘价为0.20美元。该公司的速动比率为1.00，流动比率为1.49，债务与权益比率为3.08。该公司的五十天简单移动平均线为0.21美元，其200天简单移动平均线为0.41美元。Athenex创下12个月低点0.16美元，12个月高点为1.74美元。
Athenex (NASDAQ:ATNX – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. Athenex had a negative net margin of 145.05% and a negative return on equity of 727.79%. The company had revenue of $33.53 million for the quarter, compared to analyst estimates of $28.80 million. During the same period in the prior year, the company earned ($0.33) earnings per share. As a group, analysts expect that Athenex will post -0.63 earnings per share for the current year.
Athenex（纳斯达克股票代码：ATNX — Get Rating）最后一次公布季度财报是在11月3日星期四。该公司公布了本季度每股收益（0.14美元），比市场普遍预期的0.16美元（0.16美元）高出0.02美元。Athenex的净利润率为负145.05％，负股本回报率为727.79％。该公司本季度的收入为3,353万美元，而分析师的估计为2880万美元。去年同期，该公司的每股收益（0.33美元）。作为一个整体，分析师预计，Athenex本年度的每股收益将为-0.63。
Institutional Trading of Athenex
Athenex 的机构交易
About Athenex
关于 Athenex
(Get Rating)
（获取评分）
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies.
Athenex, Inc是一家生物制药公司，从事癌症治疗药物的发现、开发和商业化。它通过三个部门运营：肿瘤学创新平台、全球供应链平台和商业平台。该公司的Orascovery候选产品包括口服紫杉醇和encequidar，一种口服剂型，正在进行转移性乳腺癌的III期试验，以及皮肤血管肉瘤、晚期胃癌和晚期实体恶性肿瘤的各种临床研究。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Athenex (ATNX)
- Is Salesforce Stock a Bargain Down Here?
- Intel is a Sleeping Giant Ready to Awaken
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- 免费获取 StockNews.com 关于 Athenex（ATNX）的研究报告的副本
- 这里的 Salesforce 股票很划算吗？
- 英特尔是准备觉醒的沉睡巨人
- 为什么 CSL Ltd 的股票值得一看
- MarketBeat：本周回顾 11/28 — 12/02
- Okta Inc庆祝盈利突破但他们能否维持增长？
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Athenex Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Athenex及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。